Crossmark

Evidence that a primary anti-viral stimulation of the immune response by OM-85 reduces susceptibility to a secondary respiratory bacterial infection in mice

Crossref DOI link: https://doi.org/10.1186/s13052-018-0569-7

Published Online: 2018-09-26

Published Print: 2018-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Rossi, Giovanni A. https://orcid.org/0000-0003-4804-2421
Bessler, Wolfgang

Ballarini, Stefania

Pasquali, Christian
Funding

Funding for this research was provided by:

OM Pharma, a company of Vifor Pharma Group (BV)
License Information

Text and Data Mining valid from 2018-09-26
More Information

Article History

Received: 5 June 2018

Accepted: 12 September 2018

First Online: 26 September 2018

Ethics approval

: Animal experiments were performed in accordance with the Institutional Guidelines and Swiss Federal and Cantonal Laws on Animal Protection.

: Not applicable

: G.A. Rossi is an active consultant for OM Pharma SA, a company of the Vifor Pharma Group, Geneva, Switzerland; W. Bessler is honorarium professor and invited guest at Albert-Ludwigs-Universität Freiburg, Germany; S. Ballarini is an employee of OM Pharma SA, a company of the Vifor Pharma Group, Geneva, Switzerland; C. Pasquali is an employee of OM Pharma SA, a company of the Vifor Pharma Group, Geneva,, Switzerland.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Document is current

Any future updates will be listed below